261 related articles for article (PubMed ID: 14751090)
1. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
Dai Y; Grant S
Curr Oncol Rep; 2004 Mar; 6(2):123-30. PubMed ID: 14751090
[TBL] [Abstract][Full Text] [Related]
2. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
4. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
6. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Senderowicz AM
Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibitors.
Dai Y; Grant S
Curr Opin Pharmacol; 2003 Aug; 3(4):362-70. PubMed ID: 12901944
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
9. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinases as targets for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitors in clinical development for the treatment of cancer.
Fischer PM; Gianella-Borradori A
Expert Opin Investig Drugs; 2003 Jun; 12(6):955-70. PubMed ID: 12783600
[TBL] [Abstract][Full Text] [Related]
14. Early development of cyclin dependent kinase modulators.
Roy KK; Sausville EA
Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitors as anticancer drugs.
Krystof V; Uldrijan S
Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
[TBL] [Abstract][Full Text] [Related]
17. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.
Wang Q; Worland PJ; Clark JL; Carlson BA; Sausville EA
Cell Growth Differ; 1995 Aug; 6(8):927-36. PubMed ID: 8547221
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase pathways as targets for cancer treatment.
Shapiro GI
J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
